December 13, 2022 at 9:25 pm

Wave Life Sciences (WVE) Rises 33% As They Enter Collaboration With GSK

Wave Life Sciences (WVE), a clinical-stage genetic medicines company, rose 33% for the day as they announced a new strategic partnership with GSK. Wave receives upfront payments of $170 million in cash and equity, and is also eligible to receive milestone payments and royalties. The collaboration brings together Wave’s PRISM oligonucleotide platform and GSK’s expertise… [Read More]
December 12, 2022 at 11:20 am

Alector, Inc. Reports Positive Safety Data in First-in-Human Study of Neurodegenerative Disease Therapeutic

Alector, Inc. (Nasdaq: ALEC), a clinical-stage immuno-neurology and immuno-oncology company, has reported positive safety and biomarker data from its first-in-human Phase 1 study of AL101, a potential treatment for neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases.  AL101 was well-tolerated and elevated progranulin levels in the cerebrospinal fluid of healthy volunteers. Highlights The study was a randomized,… [Read More]
December 08, 2022 at 9:05 pm

Celcuity (CELC) Shoots Up 26% – First Patient Dosed in Phase 3 Breast Cancer Trial

Celcuity (CELC), a clinical stage biotech company, shot up 26% for the day, shortly following their latest press release, announcing the first dosing of their Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer. “We are excited to begin enrolling patients in the VIKTORIA-1 trial and advancing towards our… [Read More]
December 07, 2022 at 9:10 pm

Prometheus Biosciences (RXDX) Surges 166% as Drug PRA023 Overshoots Drug’s Expectations

Prometheus Biosciences (RXDX) skyrocketed 166% on the news that their drug PRA023 exceeded expectations in patients with ulcerative colitis and Crohn’s disease. “Net-net, the results exceed our expectations,” said RBC Capital Markets analyst Gregory Renza. They provide “key proof-of-concept in irritable bowel disease, early validation on the biomarker strategy and positive read-through to the (second… [Read More]
December 06, 2022 at 9:06 pm

Marijuana Stocks Tank as Lawmakers Delay SAFE Banking Act

Cannabis stocks tanked today as the SAFE Banking Act may be in doubt. The new law, which would finally make it legal for banks to provide banking services to marijuana companies, is housed in a defense bill, called the NDAA, but the passage of this bill is now in question. Cannabis stocks plunged in response…. [Read More]
December 05, 2022 at 8:00 pm

Verve Therapeutics (VERV) Falls 11% on FDA Safety Concerns of Gene-Editing Approach

Verve Therapeutics (Nasdaq: VERV)  took a hit today, falling almost 10.75% as the FDA has concerns about VERV’s gene-editing approach to high cholesterol. The FDA has placed Verve’s application to begin testing on humans in the U.S. on hold – the main concern being safety, particularly worries of genetic edits becoming inheritable and unintended effects… [Read More]
December 02, 2022 at 12:10 pm

MicroBot Medical: Market Responds to New Patents; Scientific Advisory Board Appointments

Micro-robotic technology company, MicroBot Medical (Nasdaq: MBOT), has received two new patents for its LIBERTY Robotic System, the world’s first fully disposable robotic system for use in endovascular procedures. MicroBot was issued a design patent allowance by the US Patent & Trademark Office, covering its robotic system’s remote controller’s unique interface design. Highlights In November… [Read More]
December 01, 2022 at 10:33 pm

Vapotherm (VAPO) Skyrockets 52% in Positive Day for PRISM Emerging MedDevices

Vapotherm (VAPO) soared 52% for the day, with no new press releases. The most recent news coming from VAPO is an amendment to their debt agreement on November 22nd. Prior to that, Vapotherm released their Q3 earnings report, where they reported a loss and missed revenue estimates. Overall, it’s been a great day for Prism… [Read More]
December 01, 2022 at 5:13 pm

NeuroMetrix, Inc. To Launch First FDA-Approved Medical Device for Fibromyalgia

  Novel medical device and technology company, NeuroMetrix, Inc. (Nasdaq: NURO), will launch the first and only medical device authorized by the FDA to help reduce the symptoms of fibromyalgia. The full commercial launch of the company’s Quell® Fibromyalgia device is expected to take place in Q2 2023. A Pathfinder Program will be launched on… [Read More]
November 30, 2022 at 1:55 pm

IceCure’s ProSense® System First and Only Medicare Approved Cryoablation Procedure for Breast Cancer

  Cryoablation technology company, IceCure Medical (Nasdaq: ICCM) has received assignment to a Medicare Payment Group for hospital outpatient payment for its ProSense® System. ProSense is a minimally-invasive procedure that destroys early-stage breast cancer tumors by cryoablation (freezing). In October, IceCure filed a De Novo classification request with the FDA for breast cancer marketing authorization… [Read More]